Welcome to InVasc Therapeutics
Developing first-in-class drugs for the cardiometabolic market.
InVasc is a clinical stage biopharmaceutical company developing drugs to treat or prevent cardiometabolic disease. We are currently focused on advancing our two lead drugs for Chronic Kidney Disease and Atherosclerosis. Cardiovascular and metabolic diseases are the leading causes of morbidity and mortality worldwide, and collectively represent the single largest global market for pharmaceutical drug development with annual sales currently reaching $300 billion.
InVasc Therapeutics was founded in 2006 by three leading researchers at Emory University and Ohio State University with the objective of bringing new therapeutic alternatives to the market.
